Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of dendritic cell immunotherapy with Hiltonol in patients with solid tumors
2010-023139-40Phase 2Terminated
- Sponsor
- Cima Universidad de Navarra
- Start
- Nov 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poly iclc in Nonhematologic neoplasms, sponsored by Cima Universidad de Navarra. Primary endpoint: Tumor response rate. Started Nov 2010; status: terminated.
02
Drugs
poly iclc
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2010-023139-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023139-40.